Listen to the article
Colorectal Cancer Cases Rising Dramatically Among Younger Adults
A new report from the American Cancer Society reveals a concerning shift in colorectal cancer (CRC) trends, with the disease now the leading cause of cancer death in adults under 50 years old.
While CRC rates have been declining among seniors, diagnoses are rising at an alarming rate among younger populations. According to the Colorectal Cancer Statistics 2026 report published in CA: A Cancer Journal for Clinicians, adults 65 and younger now account for nearly half (45%) of all new colorectal cancer cases—a significant jump from just 27% in 1995.
The most dramatic increase is occurring among adults aged 20 to 49, with cases rising at a rate of 3% per year. The report highlights a particularly troubling statistic: 75% of colorectal cancers in adults under 50 are diagnosed at an advanced stage, when treatment is more difficult and survival rates are lower.
“After decades of progress, the risk of dying from colorectal cancer is climbing in younger generations of men and women, confirming a real uptick in disease because of something we’re doing or some other exposure,” said Rebecca Siegel, senior scientific director of surveillance research at the American Cancer Society and lead author of the report.
Half of the diagnoses in the under-50 age group occur between ages 45 and 49—the age at which routine screenings are now recommended. Yet despite eligibility for screening, only 37% of people in this age group actually undergo the potentially life-saving tests.
The report also noted a rise in rectal cancer specifically, which now comprises approximately one-third (32%) of all CRC cases, up from 27% in the mid-2000s. This shift in cancer location may have implications for treatment approaches and outcomes.
Researchers project that 158,850 new cases of colorectal cancer will be diagnosed in the United States this year, resulting in an estimated 55,230 deaths. The disease’s mortality rate is particularly tragic given that when detected at an early, localized stage, the five-year survival rate is 95%.
Health experts point to lifestyle factors as significant contributors to CRC risk. More than half of colorectal cancer cases can be linked to modifiable behaviors, including poor nutrition, high alcohol consumption, smoking, physical inactivity, and obesity.
“These findings further underscore that colorectal cancer is worsening among younger generations and highlight the immediate need for eligible adults to begin screening at the recommended age of 45,” said Dr. William Dahut, chief scientific officer at the American Cancer Society. “The report also shines a light on the crucial importance of continued funding for research to help discover new therapies to treat the disease and advance patient care.”
The medical community is calling for increased awareness of CRC symptoms among both healthcare providers and the general public. Symptoms can include persistent changes in bowel habits, rectal bleeding, abdominal discomfort, fatigue, and unexplained weight loss—though many early-stage cases produce no symptoms.
Public health advocates are emphasizing the need for broader screening participation, particularly among those in the 45-49 age bracket who now qualify for routine testing but largely aren’t receiving it. Screening methods include colonoscopy, stool tests, and newer, less invasive options that could help improve compliance rates.
While researchers continue investigating the causes behind the rising incidence in younger populations, experts stress that immediate action through screening, lifestyle modifications, and symptom awareness could save thousands of lives.
Fact Checker
Verify the accuracy of this article using The Disinformation Commission analysis and real-time sources.


29 Comments
Nice to see insider buying—usually a good signal in this space.
Good point. Watching costs and grades closely.
Uranium names keep pushing higher—supply still tight into 2026.
Nice to see insider buying—usually a good signal in this space.
Good point. Watching costs and grades closely.
The cost guidance is better than expected. If they deliver, the stock could rerate.
Good point. Watching costs and grades closely.
Good point. Watching costs and grades closely.
Exploration results look promising, but permitting will be the key risk.
Good point. Watching costs and grades closely.
Good point. Watching costs and grades closely.
Exploration results look promising, but permitting will be the key risk.
Good point. Watching costs and grades closely.
Good point. Watching costs and grades closely.
Exploration results look promising, but permitting will be the key risk.
Good point. Watching costs and grades closely.
Good point. Watching costs and grades closely.
I like the balance sheet here—less leverage than peers.
Good point. Watching costs and grades closely.
Good point. Watching costs and grades closely.
Nice to see insider buying—usually a good signal in this space.
Good point. Watching costs and grades closely.
If AISC keeps dropping, this becomes investable for me.
Production mix shifting toward Health might help margins if metals stay firm.
Good point. Watching costs and grades closely.
Good point. Watching costs and grades closely.
Interesting update on Scientists Identify Origin of Lethal Cancer Targeting Young Adults, Report Finds. Curious how the grades will trend next quarter.
Exploration results look promising, but permitting will be the key risk.
Good point. Watching costs and grades closely.